Latest News
Illumina Acquires Edico Genome to Expand Genomic Data Analysis Platform
Thursday 17 May 2018

17 May 2018 - California, US-based genetic variation analyst Illumina, Inc. (NASDAQ: ILMN) has acquired data analysis acceleration solutions provider Edico Genome, the company said.
Terms of the transaction were not disclosed.
Edico Genome's DRAGEN Bio-IT Platform (DRAGEN) uses field programmable gate array technology in conjunction with proprietary software algorithms to reduce both data footprint and time to results.
Illumina said the acquisition of Edico Genome is a big step toward realising the vision of reducing sequencing data acquisition and analysis to a push-button, standardised process.
The company expects to build on the solid foundation of DRAGEN to deliver a more streamlined and integrated sample to answer experience for customers.
The DRAGEN platform complements Illumina's sequencing portfolio and enables customers to benefit from reduced investment in compute infrastructure, and accelerated result times, to improve their overall efficiency and to allow greater emphasis on interpretation and reporting.
Illumina is improving human health by unlocking the power of the genome. The focus on innovation has established the company as a leader in DNA sequencing and array-based technologies, serving customers in the research, clinical, and applied markets. 
Date Published: 17/05/2018
Target: Edico Genome
Country: USA
Sector: Biotechnology
Type: Corporate acquisition
Status: Closed
Buyer: Illumina, Inc
Terms of the deal were not disclosed